LVRNA 012
Alternative Names: LVRNA-012Latest Information Update: 06 Oct 2022
At a glance
- Originator AIM Vaccine
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown COVID 2019 infections
Most Recent Events
- 22 Sep 2022 AIM Vaccine plans a cohort study for COVID-2019 infections (Prevention, In adults, In elderly) (IM, Injection) in September 2022 (NCT05549206)
- 16 Sep 2022 Clinical trials in COVID-2019 infections in China (IM, Injection) (NCT05550142)